Everett Vokes to Immunotherapy
This is a "connection" page, showing publications Everett Vokes has written about Immunotherapy.
Connection Strength
0.893
-
Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy. Chin Clin Oncol. 2019 Oct; 8(S1):S24.
Score: 0.403
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.117
-
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.
Score: 0.111
-
Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. Clin Lung Cancer. 2018 09; 19(5):377-386.
Score: 0.091
-
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 02; 12(2):194-207.
Score: 0.083
-
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
Score: 0.036
-
Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
Score: 0.028
-
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230.
Score: 0.025